Chemotherapy and Drug Information
A three-drug combination antiemetic therapy including aprepitant or fosaprepitant improved the prevention rate of nausea and vomiting.
In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.
Moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain.
Patients with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection of all or part of the lung if combined with chemotherapy and radiation therapy.
What is the best practice recommendation for nurse-to-patient ratio for patients receiving IL-2?
Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).
The combination of ibrutinib and chemotherapy (bendamustine and rituximab [BR]) was found to reduce the risk of death by nearly 80% in patients with previously treated CLL or SLL.
Individuals with squamous non-small cell lung cancer (NSCLC) fared better when receiving nivolumab when compared to those receiving more standard chemotherapy, according to a recent clinical trial.
The side effects caused by potent chemotherapy regimens could possibly be considerably lessened by use of an intravenous nutrition source.
Researchers have identified a molecule that may play a central role in chemotherapy resistance in patients with the most common ovarian cancer.
Stat Consult Slideshows
This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.
This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.
This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.
To view all content in our Stat Consult section, please click here.
- Younger, unrelated donors with high T cell counts make better matches for patients undergoing stem cell transplant
- Distinct triple-positive subtypes identified in breast cancer
- Managing oral oncology/hematology treatments in your practice
- Avocados may hold the answer to beating leukemia
- Viagra and other erectile dysfunction medications not found to increase melanoma risk
- Survivorship care plans: The shift back to primary care
- Scientists identify key to preventing metastatic breast cancer
- Cancer and intimate partner violence: Could you tell if one of your patients is a victim?
- Composing a CoC-compliant community health needs assessment (CHNA)
- Cancer Clusters (Fact Sheet)
- Comorbid conditions associated with worse lung cancer survival
- Benefits found for screening colonoscopies of higher quality
- High-grade cervical lesions declining in young women
- Early relapse of follicular lymphoma may increase risk of death
- Study identifies perception gap in incidence, impact of CINV/RINV
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|